Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity

Obesity (Silver Spring). 2017 Mar;25(3):510-513. doi: 10.1002/oby.21763.

Abstract

Objective: To determine the effect of prebiotic supplementation on metabolic endotoxemia and systemic inflammation in adults with overweight and obesity.

Methods: Samples from a previously conducted randomized, double-blind, placebo-controlled trial were used for analysis. Participants were randomized to 21 g of oligofructose (n = 20; BMI 30.4 kg/m2 ) or a maltodextrin placebo (n = 17; BMI 29.5 kg/m2 ) for 12 weeks. A total of 37 participants had samples available for the current analysis. Resistin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and macrophage chemoattractant protein-1 (MCP-1) were quantified using MILLIPLEX® assays. Lipopolysaccharide (LPS) was measured using PyroGene™ Recombinant Factor C Assay.

Results: Plasma LPS concentrations were reduced by 40% in the oligofructose group over 12 weeks compared to a 48% increase in the placebo group (P = 0.04). PAI-1, a risk factor for thrombosis, was reduced to a greater extent in the oligofructose group (-17.3 ± 2.6 ng/ml) compared to the placebo group (-9.7 ± 1.8 ng/ml; P = 0.03). Oligofructose did not affect IL-6, TNF-α, MCP-1, adiponectin, or resistin.

Conclusions: Oligofructose reduces metabolic endotoxemia and PAI-1. Incorporating prebiotics into the diet through supplements or functional foods may help mitigate some markers of obesity-associated inflammation.

Trial registration: ClinicalTrials.gov NCT00522353.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adiponectin / blood
  • Adult
  • Biomarkers / blood
  • Chemokine CCL2 / blood
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / complications
  • Inflammation / drug therapy*
  • Interleukin-6 / blood
  • Lipopolysaccharides / blood*
  • Male
  • Middle Aged
  • Oligosaccharides / pharmacology
  • Oligosaccharides / therapeutic use*
  • Overweight / blood
  • Overweight / complications
  • Overweight / drug therapy*
  • Plasminogen Activator Inhibitor 1 / blood
  • Prebiotics*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / blood

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Biomarkers
  • Chemokine CCL2
  • IL6 protein, human
  • Interleukin-6
  • Lipopolysaccharides
  • Oligosaccharides
  • Plasminogen Activator Inhibitor 1
  • Prebiotics
  • SERPINE1 protein, human
  • Tumor Necrosis Factor-alpha
  • oligofructose

Associated data

  • ClinicalTrials.gov/NCT00522353